• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Advanced functional materials >Ruthenium (Ⅱ)-Coordinated Supramolecular Metallodrug Complex Realizing Oxygen Self-Supply In Situ for Overcoming Hypoxic Tumors
【24h】

Ruthenium (Ⅱ)-Coordinated Supramolecular Metallodrug Complex Realizing Oxygen Self-Supply In Situ for Overcoming Hypoxic Tumors

机译：Ruthenium (Ⅱ)-Coordinated Supramolecular Metallodrug Complex Realizing Oxygen Self-Supply In Situ for Overcoming Hypoxic Tumors

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相关主题

摘要

Tumor hypoxia greatly limits the antitumor therapeutic efficacy of oxygen (O-2)-dependent treatments. The common strategies of doping O-2 generating compounds into one "package" may lead to insufficient O-2 supply in situ in cancer cells due to the relatively low loading content, limited reproducibility, and uncontrollable release kinetics. Herein, organometallic drug complexes combined with a supramolecular interaction strategy are proposed to realize a stable and efficient O-2 self-supply in situ for overcoming hypoxic tumors. A ruthenium (II)-coordinated supramolecular metallodrug complex (RuSMDC) is first designed and synthesized via host-guest interactions between two functionalized drug molecules, in which ruthenium is used to catalyze the decomposition of hydrogen peroxide to produce O-2. The obtained RuSMDC further self-assembles into Ru-containing supramolecular metallodrug micelles (RuSMDMs), which provides sufficient O-2 for chemotherapy and photodynamic therapy (PDT) oncotherapy in an anaerobic tumor environment. In vitro and in vivo studies further confirm that RuSMDMs effectively alleviate the tumor hypoxic environment, greatly improve the therapeutic effect of chemotherapy and PDT oncotherapy, and reduce the systemic toxicity to normal organs.

著录项

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号